NCT06747247View on ClinicalTrials.gov

MT1013 Injection for the Treatment of Patients With Secondary Hyperparathyroidism (SHPT) Undergoing Maintenance Dialysis

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

April 7, 2023

Primary Completion Date

June 8, 2025

Study Completion Date

August 30, 2025

Conditions
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Interventions
DRUG

MT1013

MT1013 is a dual-agonist polypeptide, not only to control iPTH levels in SHPT patients on maintainence dialysis, but also promote bone formation.

DRUG

Placebo

Appear similar to MT1013, but has no treatment effect.

Trial Locations (1)

310003

RECRUITING

First Affiliated Hospital College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

INDUSTRY